研究单位：[1]Chinese SLE Treatment and Registration Group[2]Beijing Municipal Science & Technology Commission[3]North China Pharmaceutical Group Corporation[4]Peking Union Medical College Hospital,Beijing,Beijing,China,100053[5]Shenzhen People''s Hospital,Shenzhen,Guangdong,China[6]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[7]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[8]The First Hospital of China Medical University,Shenyang,Liaoning,China[9]First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China
This is a multi-center, double-blinded, randomized, placebo-controlled, phase 2 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
